Trials / Unknown
UnknownNCT04024241
Medium Dose of Cytarabine and Mitoxantrone
The Clinical Observationg on HAM for Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- Shenzhen People's Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.
Detailed description
The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Flow Cytometer | high dose |
| DRUG | Mitoxantrone | high dose |
| DRUG | Cytarabine | high dose |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
- First posted
- 2019-07-18
- Last updated
- 2019-07-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04024241. Inclusion in this directory is not an endorsement.